Australian biotechnology company NeuroScientific Biopharmaceuticals (ASX:NSB) has reached another milestone in its clinical development program, with the commencement of treatment under the Special Access Scheme for its patented StemSmart mesenchymal stem cell therapy in a fourth patient. …
NeuroScientific advances StemSmart therapy with fourth patient treated in Crohn’s disease program
November 11, 2025 Australian Biotech
Latest Video
New Stories
-
RAGE Biotech raises $29 million and appoints new leadership to advance precision RNA therapeutics
November 13, 2025 - - Latest News -
Nanosonics names new North American president ahead of CORIS launch
November 13, 2025 - - Australian Biotech -
Australians open to AI in healthcare, but prefer doctors to be in control
November 13, 2025 - - Latest News -
Every Government agency to appoint a 'Chief AI Officer' under national plan
November 12, 2025 - - Latest News -
New Zealand accelerates medicines reform with major regulatory changes
November 12, 2025 - - Latest News -
FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health
November 12, 2025 - - Latest News -
Optometry Australia and Alcon launch scholarship fund to support First Nations eye health leaders
November 12, 2025 - - Latest News